Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 245

1.

Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease.

Cătană CS, Berindan Neagoe I, Cozma V, Magdaş C, Tăbăran F, Dumitraşcu DL.

World J Gastroenterol. 2015 May 21;21(19):5823-30. doi: 10.3748/wjg.v21.i19.5823. Review.

2.

The IL-23/IL-17 pathway in inflammatory bowel disease.

Geremia A, Jewell DP.

Expert Rev Gastroenterol Hepatol. 2012 Apr;6(2):223-37. doi: 10.1586/egh.11.107. Review.

PMID:
22375527
3.

Innate and adaptive immunity in inflammatory bowel disease.

Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A.

Autoimmun Rev. 2014 Jan;13(1):3-10. doi: 10.1016/j.autrev.2013.06.004. Epub 2013 Jun 15. Review.

PMID:
23774107
4.

Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases.

Owaga E, Hsieh RH, Mugendi B, Masuku S, Shih CK, Chang JS.

Int J Mol Sci. 2015 Sep 1;16(9):20841-58. doi: 10.3390/ijms160920841. Review.

5.

IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid.

Rafa H, Saoula H, Belkhelfa M, Medjeber O, Soufli I, Toumi R, de Launoit Y, Moralès O, Nakmouche M, Delhem N, Touil-Boukoffa C.

J Interferon Cytokine Res. 2013 Jul;33(7):355-68. doi: 10.1089/jir.2012.0063. Epub 2013 Mar 8.

PMID:
23472658
6.

The interleukin-23 axis in intestinal inflammation.

Ahern PP, Izcue A, Maloy KJ, Powrie F.

Immunol Rev. 2008 Dec;226:147-59. doi: 10.1111/j.1600-065X.2008.00705.x. Review.

PMID:
19161422
7.

IL-23/IL-17 axis in IBD.

Sarra M, Pallone F, Macdonald TT, Monteleone G.

Inflamm Bowel Dis. 2010 Oct;16(10):1808-13. doi: 10.1002/ibd.21248. Review.

PMID:
20222127
8.

Th17 plasticity and its changes associated with inflammatory bowel disease.

Ueno A, Ghosh A, Hung D, Li J, Jijon H.

World J Gastroenterol. 2015 Nov 21;21(43):12283-95. doi: 10.3748/wjg.v21.i43.12283. Review.

9.

Inflammatory bowel disease: beyond the boundaries of the bowel.

Actis GC, Rosina F, Mackay IR.

Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):401-10. doi: 10.1586/egh.11.23. Review.

PMID:
21651357
10.

Recent advances in IBD pathogenesis: genetics and immunobiology.

Shih DQ, Targan SR, McGovern D.

Curr Gastroenterol Rep. 2008 Dec;10(6):568-75. Review.

11.

Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease.

Xu XR, Liu CQ, Feng BS, Liu ZJ.

World J Gastroenterol. 2014 Mar 28;20(12):3255-64. doi: 10.3748/wjg.v20.i12.3255. Review.

12.

Interleukin-23/Th17 pathways and inflammatory bowel disease.

Abraham C, Cho J.

Inflamm Bowel Dis. 2009 Jul;15(7):1090-100. doi: 10.1002/ibd.20894. Review.

PMID:
19253307
13.

Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.

Kanai T, Nemoto Y, Kamada N, Totsuka T, Hisamatsu T, Watanabe M, Hibi T.

Curr Opin Gastroenterol. 2009 Jul;25(4):306-13. doi: 10.1097/MOG.0b013e32832bc627. Review.

PMID:
19448533
14.

Immunopathogenesis of IBD: Batf as a Key Driver of Disease Activity.

Hildner K, Punkenburg E, Abendroth B, Neurath MF.

Dig Dis. 2016;34 Suppl 1:40-7. doi: 10.1159/000447281. Epub 2016 Aug 22.

PMID:
27548324
15.

Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease.

Friedrich M, Diegelmann J, Schauber J, Auernhammer CJ, Brand S.

Mucosal Immunol. 2015 Jul;8(4):943-58. doi: 10.1038/mi.2014.124. Epub 2014 Dec 10.

PMID:
25492478
16.

miRNAs as new molecular insights into inflammatory bowel disease: Crucial regulators in autoimmunity and inflammation.

Xu XM, Zhang HJ.

World J Gastroenterol. 2016 Feb 21;22(7):2206-18. doi: 10.3748/wjg.v22.i7.2206. Review.

17.

Th17 cytokines in inflammatory bowel diseases: discerning the good from the bad.

Troncone E, Marafini I, Pallone F, Monteleone G.

Int Rev Immunol. 2013 Oct-Dec;32(5-6):526-33. doi: 10.3109/08830185.2013.823421. Epub 2013 Sep 16. Review.

PMID:
24041379
18.

TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis.

Wedebye Schmidt EG, Larsen HL, Kristensen NN, Poulsen SS, Lynge Pedersen AM, Claesson MH, Pedersen AE.

Inflamm Bowel Dis. 2013 Jul;19(8):1567-76. doi: 10.1097/MIB.0b013e318286fa1c.

PMID:
23689808
19.

Synergy of IL-23 and Th17 cytokines: new light on inflammatory bowel disease.

Shen W, Durum SK.

Neurochem Res. 2010 Jun;35(6):940-6. doi: 10.1007/s11064-009-0091-9. Epub 2009 Nov 14. Review.

PMID:
19915978
20.

RORγt-dependent IL-17A-producing cells in the pathogenesis of intestinal inflammation.

Kanai T, Mikami Y, Sujino T, Hisamatsu T, Hibi T.

Mucosal Immunol. 2012 May;5(3):240-7. doi: 10.1038/mi.2012.6. Epub 2012 Feb 22. Review.

PMID:
22354322

Supplemental Content

Support Center